Journals / Retina-Vitreus / 2005 / Cilt: 13 - Sayı: 3

24 months follow-up results in ocular photodynamic therapy

Oküler fotodinamik tedavide 24 aylık sonuçlarımız

Pages
173–178
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Similar results seen in TAP and VIP studies can be achieved with a less number of session per patient.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: This study was performed to investigate the efficacy of ocular photodynamic therapy (OPT) with verteporfin (Visudyne) in AMD and non-AMD(NAMD) cases in addition to share our experience in its clinical practice.
📊
Key Findings & Data:Materials and Methods: OPT performed patients during the period of May 2001 -2003 were included in the study.
💡
Conclusion & Impact:Similar results seen in TAP and VIP studies can be achieved with a less number of session per patient.
🔬Design:Research Article
📍Scope:2001 -2003 Verileri
⚙️Variables:Oftalmoskopi · Floresan anjiyografi · Maküler dejenerasyon

Abstract

Purpose: This study was performed to investigate the efficacy of ocular photodynamic therapy (OPT) with verteporfin (Visudyne) in AMD and non-AMD(NAMD) cases in addition to share our experience in its clinical practice. Materials and Methods: OPT performed patients during the period of May 2001 -2003 were included in the study. All patients were grouped in 2 groups as AMD and NAMD. Total population of 256 patients with a mean age of 69,02±13,07 years (range 28-91 years) was composed of 213 AMD patients with a mean age of 72,83±9.03 years (range 43-91 years) and 43 NAMD patients with a mean age of 50,16±13,71 years (28-86 years). In all patients, therapy indications and follow up guidelines were formed according to the TAP and VIP study results and visual acuity measured by ETDRS charts, Fundus Fluorescein Angiography (FFA) and binocular indirect ophthalmoscopic features were used as main outcome measures. Minimum 3 and maximum 24 months (mean: 8,53±5,42 months) follow up results were discussed in the study. Results: Snellen equivalent mean visual acuity values of the patients in toto before and after the therapy were 0,2202±0,1541 (min:0,01 max:0,7) and 0,264±0,259 (min:0,01 max:1,0), respectively. Success rates of the therapy in groups were as follows: 31,5% unsuccessful, 54,9% successful, and 13,7% still in follow-up in AMD Group and 11,6% unsuccessful, 76,7% successful, and 11,6% still in follow-up in NAMD Group. Conclusion: OPT is potentially the most successful and safest therapeutic alternative in selected active CNVs associated with AMD or non-AMD causes in the means of either ocular or systemic complications and adverse events. Similar results seen in TAP and VIP studies can be achieved with a less number of session per patient.

Özet

Amaç: Bu çalışma, yaşa bağlı makula dejenerasyonu (AMD) ile ilişkili ve AMD ile ilişkili olmayan subfoveal koroid neovaskularizasyonlu (CNV) seçilmiş olgularda verteporfin (Visudyne) ile uygulanan Oküler Fotodinamik Tedavi (OPT)'nin etkinliğini araştırmak ve klinik uygulamalarımızdaki deneyimlerimizi paylaşmak üzere tasarlanmıştır. Gereç ve Yöntem: Kliniğimizde Mayıs 2001-Mayıs 2003 tarihleri arasında OPT uygulanmış olgular çalışma kapsamına alınmıştır. Olgular, subfoveal koroid neovaskülarizasyonu (CNV) nedenine göre, "yaşa bağlı makula dejenerasyonuyla (AMD) ilişkili (AMD grubu)" ve "AMD ilişkili olmayan (NAMD grubu)" olarak 2 gruba ayrılmıştır. Yaşları 28-91 yıl arasında değişen ortalama 69,02±13,07 yaşındaki toplam 256 olguluk populasyonunun 213 olgudan oluşan AMD grubundaki yaş sınırı 43-91 (ort:72,83±9.03) yıl, 43 olgudan oluşan NAMD grubundaki yaş sınırı 28-86 (ort: 50,16±13,71) yıldır. Hastaların tümünde, tedavi endikasyonu ve takibinde, TAP ve VIP çalışmalarında olduğu gibi ETDRS eşeliyle en iyi düzeltilmiş görme keskinliği değeri ile binoküler oftalmoskopi ve Fundus Floresein Anjiografi (FFA) bulguları esas alınmıştır. Olguların minimum 3 ay, maksimum 24 aylık takip sonuçları çalışma kapsamına dahil edilerek ortalama 8,53±5,42 aylık takiplerinin neticeleri sunulmuştur. Bulgular: Hastaların Snellen eşdeğeri olarak görme keskinliği seviyeleri tedavi öncesinde ortalama 0,2202±0,1541 (min:0,01 maks:0,7) iken tedavi sonrasında 0,264±0,259 (min:0,01 maks:1,0) olarak saptanmıştır. Grupların başarı sonuçlarına bakıldığında, tedavinin AMD grubunda %31,5 oranla başarısız, %54,9 oranla başarılı, olduğu gözlenirken olguların %13,7'sinin hâlâ takip edildiği; NAMD grubunda ise %11,6 oranla başarısız, %76,7 oranla başarılı, %11,6 oranla hâlâ takipte olduğu saptanmıştır. Sonuç: OPT, AMD ve AMD dışı nedenlerle aktif koroid neovaskülarizasyonuna sahip uygun olgularda, klinik olarak kullanımda olan mevcut tedavi alternatifleri içinde, başarı şansı en yüksek, hastayı gerek sistemik gerekse oküler açıdan en az riske sokan başarılı bir tedavi seçeneğidir. TAP ve VIP çalışmalarındakine benzer sonuçlar daha az uygulama ile de elde edilebilmektedir.

🔖

Cite This Article

YETİK, H., MÜFTÜOĞLU, G., AKAR, S., ARAS, C., ÖZKAN, Ş. (2005). 24 months follow-up results in ocular photodynamic therapy. Retina-Vitreus, Cilt: 13 - Sayı: 3, 173–178. https://ajindex.com/articles/305291

References (11)

  1. Nseyo UO, Dougherty TJ, Boyle DG, et al.: Whole bladder photodynamic therapy for transitional cell carcinoma of bladder. Urology. 1985 Sep;26:274-280
  2. Camps JL Jr, Powers SK, Beckman WC Jr, et al.: Photodynamic therapy of prostate cancer: an in vitro study. J Urol. 1985 Dec;134:1222-1226
  3. Canakis C, Conway MD, Livir-Rallatos C, et al.: Ocular photodynamic therapy in choroidal neovascularization complicating idiopathic central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging. 2004 Mar-Apr;35(2):168-171
  4. Verteporfin Roundtable 2000 and 2001 Participants; Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators; Verteporfin in photodynamic therapy (VIP) study group principal investigators. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Novariis Ophthalmics Inc., Duluth, GA 30097, USA. Retina. 2002 Feb;22:6-18
  5. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999 Oct;117:1329-1345. Erratum in: Arch Ophthalmol 2000 Apr;118:488
  6. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1 -year results of a randomized clinical trial VIP report no
  7. Ophthalmology. 2001 May;108:841-52
  8. Saperstein DA, Rosenfeld PJ, Bressler NM, et al.: Verteporfin in Ocular Histoplasmosis (VOH) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology. 2002 Aug;109:1499-505
  9. Bressler SB, Pieramici DJ, Koester JM, et al: Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management--TAP report No
  10. Arch Ophthalmol. 2004 Mar;122:325-329
  11. Bressler NM, Arnold J, Benchaboune M, et al.: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients wi